Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society

Abstract

is not recommended whilst anti-acid therapy may be considered in patients without advanced disease.

Complete resolution of apparently definite radiological and histological usual interstitial pneumonia

“…In contrast to our patient's subacute clinical presentation, IPF is classically associated with a more insidious onset and chronic course. [1] Our patient's convincing radiological and histopathological diagnosis of IPF was discordant with his clinical presentation, causing us to consider alternative diagnoses. His history of cave running 5 months before, although tantalising for a fungal infection, was deemed too long before presentation to be the cause in an immunocompetent individual, and was additionally excluded on both histology and culture.…”

“…Idiopathic pulmonary fibrosis (IPF) is considered to be the most common form of pulmonary fibrosis. [1] It is progressive and irreversible, with a reported median survival of ~3 years. [1,2] The pathological correlate is usual interstitial pneumonia (UIP).…”

“…[1] It is progressive and irreversible, with a reported median survival of ~3 years. [1,2] The pathological correlate is usual interstitial pneumonia (UIP). The presentation tends to be insidious, with imaging features that are irreversible and progressive.…”

Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

“…The international ATS/ERS/JRS/ ALAT guidelines for the treatment of IPF patients explicitly recommend palliative care targeted at symptoms (palliation) as a mandatory component, complementary to specific (antifibrotic) treatment targeted at the underlying disease [10]. Such care should be offered to the patient at least from the moment the disease enters the advanced stage or the first life-threatening exacerbation occurs [331,358,359]. In advanced and terminal IPF stages patient care should be provided by trained multidisciplinary teams of home and inpatient care.…”

Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep

“…Among issues highlighted by the TSANZ/LFA position statement on IPF treatment is the need for a holistic approach, with particular focus on co‐morbidities and non‐pharmacological treatments and on the challenges due to geographical differences as well as funding criteria restrictions . Position statements from number of countries have also been published over the last years …”